Open Access. Powered by Scholars. Published by Universities.®
Immunoprophylaxis and Therapy Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
Articles 1 - 2 of 2
Full-Text Articles in Immunoprophylaxis and Therapy
In Vitro Assessment Of The Antihistomonal Activity Of Methyl Jasmonate And Jasmonic Acid, Mckayla B. Williams
In Vitro Assessment Of The Antihistomonal Activity Of Methyl Jasmonate And Jasmonic Acid, Mckayla B. Williams
Poultry Science Undergraduate Honors Theses
Histomonas meleagridis is a protozoan parasite and the causative agent of histomonosis in gallinaceous birds. There are currently no approved prevention or treatment options available for histomonosis control in the United States. Mortality in affected turkey flocks can exceed 80% which highlights the urgent need for research investigating novel strategies to mitigate histomonosis in the field. The objective of this study was to evaluate the in vitro antihistomonal and antibacterial effects of of methyl jasmonate (MeJA) and jasmonic acid (JA), two plant-derived compounds, in a xenic culture of H. meleagridis. Assays were conducted using cultured H. meleagridis (PHL strain) treated …
Immunotherapeutic Strategies To Reverse Tumor Associated Immunosuppression In Breast Cancer, Sruthi Ravindranathan
Immunotherapeutic Strategies To Reverse Tumor Associated Immunosuppression In Breast Cancer, Sruthi Ravindranathan
Graduate Theses and Dissertations
Heterogenous cancers such as breast carcinoma, would highly benefit from personalized vaccine approaches such as autologous tumor cell vaccines (ATCVs). By using cancer cells that are isolated from self, this approach has the potential to generate a polyclonal immune response against tumor antigens, that are specific to the individual. However, so far, ATCVs against breast cancers have not had any clinical success due to the poor immunogenicity of the malignant cells.
In this study, for the first time, we determined tumor derived G-CSF to play a major role in affecting immune response against breast cancer ATCVs. By using CRISPR/Cas9 genome …